64 citations · 74 across the 4 of their papers we have counts for
4 papers
Designing an exploratory phase 2b platform trial in NASH with correlated, co-primary binary endpoints
Elias Laurin Meyer, Peter Mesenbrink, Nicholas A. Di Prospero +5
Non-alcoholic steatohepatitis (NASH) is the progressive form of nonalcoholic fatty liver disease (NAFLD) and a disease with high unmet medical need. Platform trials provide great b…
CohortPlat: Simulation of cohort platform trials investigating combination therapies
Elias Laurin Meyer, Peter Mesenbrink, Cornelia Dunger-Baldauf +2
Platform trials have gained a lot of attention recently as a possible remedy for time-consuming classical two-arm randomized controlled trials, especially in early phase drug devel…
On model-based time trend adjustments in platform trials with non-concurrent controls
Marta Bofill Roig, Pavla Krotka, Carl-Fredrik Burman +9
Platform trials can evaluate the efficacy of several treatments compared to a control. The number of treatments is not fixed, as arms may be added or removed as the trial progresse…
Pseudo-domains in imaging data improve prediction of future disease status in multi-center studies
Matthias Perkonigg, Peter Mesenbrink, Alexander Goehler +3
In multi-center randomized clinical trials imaging data can be diverse due to acquisition technology or scanning protocols. Models predicting future outcome of patients are impaire…